Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study

•Real-life data on the treatment of 1239 patients with advanced NSCLC in Germany.•Carboplatin versus cisplatin: similar overall survival (mOS 12 months) and HRQOL.•Outcome in routine care was comparable to outcome in randomized clinical trials.•The symptoms fatigue, nausea, dyspnoea and pain need special attention.•Patients treated with TKIs had superior outcome and HRQOL.